Information Provided By: 
Fly News Breaks for April 17, 2018
RIGL
Apr 17, 2018 | 19:09 EDT
Piper Jaffray analyst Christopher Raymond raised his price target on Rigel Pharmaceuticals to $7 from $6 and kept his Overweight rating after the FDA approval of Tavalisse "with a broad label" as had been hoped. Raymond says the FDA decision navigated successfully through "some degree of controversy" for the company, adding that are "reasonable expectations" for revenues going forward.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
